TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
MWN-AI** Summary
TuHURA Biosciences, Inc. (NASDAQ:HURA), a Phase 3 immuno-oncology company, announced on February 26, 2026, that it has regained compliance with Nasdaq's $1.00 minimum bid price requirement. This confirmation follows a period during which TuHURA's stock consistently traded at or above the $1.00 mark for 11 consecutive business days, from February 10 to February 25, 2026. The positive news was attributed to the resurgence in stock price, thereby closing the compliance matter with Nasdaq.
Dr. James Bianco, the President and CEO, expressed satisfaction with the achievement, emphasizing the company's renewed commitment to advancing its drug development pipeline. TuHURA continues to make strides in clinical trials, particularly with its lead product candidate, IFX-2.0. This therapy is currently undergoing a Phase 3 trial as an adjunctive treatment for patients with advanced or metastatic Merkel Cell Carcinoma, alongside the checkpoint inhibitor Keytruda® (pembrolizumab).
Additionally, TuHURA is poised to initiate a Phase 2 study of TBS-2025, a VISTA inhibiting monoclonal antibody, aimed at treating relapsed/refractory NPM1 mutated Acute Myeloid Leukemia (AML). The company is also focused on the ongoing development of innovative therapies, including first-in-class immune-modulating antibody drug conjugates.
TuHURA Biosciences has traded under challenging market conditions, but this recent compliance achievement marks a notable turnaround. Investors and stakeholders are encouraged to visit the company's website for more information and updates on its clinical trials and future endeavors in the field of immuno-oncology. The company continues to navigate forward with a focus on combating the complexities of cancer treatment resistance.
MWN-AI** Analysis
TuHURA Biosciences Inc. (NASDAQ: HURA) recently announced its compliance with Nasdaq's minimum bid price requirement, a significant milestone for a company actively engaged in the high-stakes immuno-oncology sector. The stock closing at or above $1.00 per share for 11 consecutive days signals a potential rebounding confidence from investors, which is essential for any biotech firm, especially as it approaches critical clinical trials.
The company’s focus on innovative therapeutics for overcoming resistance to cancer immunotherapy positions it at the forefront of cancer treatment advancements. Its lead candidate, IFx-2.0, is currently in a Phase 3 clinical trial for Merkel Cell Carcinoma, while the promising TBS-2025 therapy is set to enter Phase 2 trials for a distinct type of leukemia. These developments underline TuHURA's commitment to pipeline advancement and innovation, both of which are vital for sustained investor interest and market capitalization stability.
Investors should closely monitor TuHURA’s trial outcomes and enrollment progress. Positive results from these clinical trials could catalyze higher stock valuations, while regulatory approvals might further enhance its market credibility. However, potential investors should remain cautious. The biotech industry is highly volatile; trial failures or delays in regulatory approvals can significantly impact stock prices.
Additionally, the regaining of Nasdaq compliance may attract institutional investors who prefer companies meeting listing requirements, thus potentially increasing trading volumes and stabilizing prices. This compliance also alleviates immediate pressure on management, allowing a focused strategy on growth and innovation.
In summary, while TuHURA's recent compliance news is a bullish indicator, investors should keep a tactical approach by incorporating risk management strategies and closely following clinical milestones as they unfold.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
TAMPA, Fla., Feb. 27, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that on February 26, 2026, it received written notice from the Nasdaq Stock Market LLC (Nasdaq) confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the "Listing Rule"). Nasdaq confirmed that for the last 11 consecutive business days, from February 10, 2026, through February 25, 2026, the closing bid price of the Company's common stock has been at $1.00 per share or greater, and as a result, the matter is now closed.
"We are pleased to have regained full compliance with Nasdaq's listing standards and continue to remain fully focused on advancing our pipeline of assets," said Dr. James Bianco, President and CEO of TuHURA Biosciences. "We continue to progress enrollment in our Phase 3 accelerated approval trial for IFX-2.0 in front-line Merkel Cell Carcinoma; are readying TBS 2025, our VISTA inhibiting antibody, for the initiation of our Phase 2 study in relapsed/refractory NPM1 mutated AML; and are continuing to advance toward preclinical proof-of-concept in our first-in-class immune modulating antibody drug conjugates."
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.
TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
In addition to its innate immune agonist product candidates, TuHURA acquired TBS-2025 in its merger with Kineta Inc. on June 30, 2025. TBS-2025 is a VISTA inhibiting mAb moving into Phase 2 development in mutNPM1 r/r AML. In addition, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of, and subject to the safe harbor created by Section 27A of the Securities Act, Section 21E of the Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These Forward-Looking Statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases, you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely," or the negative or plural of these words or similar expressions. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the SEC, which are available on TuHURA's website and at www.sec.gov.
The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Investor Contact:
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com
SOURCE TuHURA Biosciences, Inc.
FAQ**
What specific strategies is TuHURA Biosciences Inc. (NASDAQ: HURA) implementing to maintain its compliance with Nasdaq's listing standards beyond the recent bid price recovery?
How does TuHURA Biosciences Inc. (NASDAQ: HURA) plan to address potential challenges related to the enrollment in its Phase 3 trial for IFX-2.0 amid ongoing market conditions?
With TuHURA Biosciences Inc. (NASDAQ: HURA) now compliant with Nasdaq's minimum bid price requirement, how does the company intend to leverage this status in attracting more investors or partners?
Can TuHURA Biosciences Inc. (NASDAQ: HURA) provide insights into its timelines and expected milestones for its pipeline developments, particularly for the Phase 2 study of TBS-2025 and the immune modulating antibody drug conjugates?
**MWN-AI FAQ is based on asking OpenAI questions about TuHURA Biosciences Inc. (NASDAQ: HURA).
NASDAQ: HURA
HURA Trading
1.79% G/L:
$1.99 Last:
64,008 Volume:
$1.94 Open:
